A new non-invasive approach based on polyhexamethylene biguanide increases the regression rate of HPV infection

Antonio Gentile, Sandro Gerli, Gian Carlo Di Renzo, Antonio Gentile, Sandro Gerli, Gian Carlo Di Renzo

Abstract

Background: HPV infection is a worldwide problem strictly linked to the development of cervical cancer. Persistence of the infection is one of the main factors responsible for the invasive progression and women diagnosed with intraepithelial squamous lesions are referred for further assessment and surgical treatments which are prone to complications. Despite this, there are several reports on the spontaneous regression of the infection.This study was carried out to evaluate the effectiveness of a long term polyhexamethylene biguanide (PHMB)-based local treatment in improving the viral clearance, reducing the time exposure to the infection and avoiding the complications associated with the invasive treatments currently available.

Method: 100 women diagnosed with HPV infection were randomly assigned to receive six months of treatment with a PHMB-based gynecological solution (Monogin®, Lo.Li. Pharma, Rome - Italy) or to remain untreated for the same period of time.

Results: A greater number of patients, who received the treatment were cleared of the infection at the two time points of the study (three and six months) compared to that of the control group. A significant difference in the regression rate (90% Monogin group vs 70% control group) was observed at the end of the study highlighting the time-dependent ability of PHMB to interact with the infection progression.

Conclusions: The topic treatment with PHMB is a preliminary safe and promising approach for patients with detected HPV infection increasing the chance of clearance and avoiding the use of invasive treatments when not strictly necessary.

Trial registration: ClinicalTrials.gov Identifier NCT01571141.

References

    1. Johnson CY, Sharp L, Cotton SC, Harris CA, Gray NM, Little J. Human papillomavirus infection and anxiety: analyses in women with low-grade cervical cytological abnormalities unaware of their infection status. PLoS One. 2011;6(6):e21046. doi: 10.1371/journal.pone.0021046.
    1. Johnson AM, Mercer CH, Beddows S, de Silva N, Desai S, Howell-Jones R, Carder C, Sonnenberg P, Fenton KA, Lowndes C. et al.Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain. Sex Transm Infect. 2012;88(3):212–217. doi: 10.1136/sextrans-2011-050306.
    1. Sorbye SW, Arbyn M, Fismen S, Gutteberg TJ, Mortensen ES. Triage of women with low-grade cervical lesions–HPV mRNA testing versus repeat cytology. PLoS One. 2011;6(8):e24083. doi: 10.1371/journal.pone.0024083.
    1. Wright TC Jr. Cox JT, Massad LS, Twiggs LB, Wilkinson EJ: 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287(16):2120–2129. doi: 10.1001/jama.287.16.2120.
    1. Zanotti KM, Belinson J. Update on the diagnosis and treatment of human papillomavirus infection. Cleve Clin J Med. 2002;69(12):948. doi: 10.3949/ccjm.69.12.948. 951–945, 956 passim.
    1. Chan JK, Monk BJ, Brewer C, Keefe KA, Osann K, McMeekin S, Rose GS, Youssef M, Wilczynski SP, Meyskens FL. et al.HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3. Br J Cancer. 2003;89(6):1062–1066. doi: 10.1038/sj.bjc.6601196.
    1. Hubner NO, Kramer A. Review on the efficacy, safety and clinical applications of polihexanide, a modern wound antiseptic. Skin Pharmacol Physiol. 2010;23(Suppl):17–27.
    1. Valluri S, Fleming TP, Laycock KA, Tarle IS, Goldberg MA, Garcia-Ferrer FJ, Essary LR, Pepose JS. In vitro and in vivo effects of polyhexamethylene biguanide against herpes simplex virus infection. Cornea. 1997;16(5):556–559.
    1. Passic SR, Ferguson ML, Catalone BJ, Kish-Catalone T, Kholodovych V, Zhu W, Welsh W, Rando R, Howett MK, Wigdahl B. et al.Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1. Biomed Pharmacother. 2010;64(10):723–732. doi: 10.1016/j.biopha.2010.10.001.
    1. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr. et al.The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114–2119. doi: 10.1001/jama.287.16.2114.
    1. Sellors JW, Sankaranarayanan R. Colposcopy and Treatment of Cervical Intraepithelial Neoplasia. World Health Organization: A Beginners' Manual; 2003.
    1. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(3):1–10.
    1. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423–428. doi: 10.1056/NEJM199802123380703.
    1. Krebs FC, Miller SR, Ferguson ML, Labib M, Rando RF, Wigdahl B. Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1. Biomed Pharmacother. 2005;59(8):438–445. doi: 10.1016/j.biopha.2005.07.007.
    1. Marelli G, Papaleo E, Origoni M, Caputo L, Ferrari A. Polyhexamethylene biguanide for treatment of external genital warts: a prospective, double-blind, randomized study. Eur Rev Med Pharmacol Sci. 2005;9(6):369–372.
    1. Werthen M, Davoudi M, Sonesson A, Nitsche DP, Morgelin M, Blom K, Schmidtchen A. Pseudomonas aeruginosa-induced infection and degradation of human wound fluid and skin proteins ex vivo are eradicated by a synthetic cationic polymer. J Antimicrob Chemother. 2004;54(4):772–779. doi: 10.1093/jac/dkh407.
    1. Fabry W, Trampenau C, Bettag C, Handschin AE, Lettgen B, Huber FX, Hillmeier J, Kock HJ. Bacterial decontamination of surgical wounds treated with Lavasept. Int J Hyg Environ Health. 2006;209(6):567–573. doi: 10.1016/j.ijheh.2006.03.008.
    1. Yoon CS, Kim KD, Park SN, Cheong SW. alpha(6) Integrin is the main receptor of human papillomavirus type 16 VLP. Biochem Biophys Res Commun. 2001;283(3):668–673. doi: 10.1006/bbrc.2001.4838.
    1. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, Jansen KU, Keller PM. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem. 1999;274(9):5810–5822. doi: 10.1074/jbc.274.9.5810.
    1. Aplin AE, Howe A, Alahari SK, Juliano RL. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev. 1998;50(2):197–263.
    1. Van der Flier A, Sonnenberg A. Function and interactions of integrins. Cell Tissue Res. 2001;305(3):285–298. doi: 10.1007/s004410100417.
    1. Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. J Appl Microbiol. 2005;99(4):703–715. doi: 10.1111/j.1365-2672.2005.02664.x.
    1. Kirschberg T, Parrish J. Metal chelators as antiviral agents. Curr Opin Drug Discov Devel. 2007;10(4):460–472.
    1. Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A. 2009;106(48):20458–20463. doi: 10.1073/pnas.0908502106.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する